Video

REVIEW UroToday

Enhancing Androgen Blockade in Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC) VL

Search

Navigating Non-Metastatic Castration-Resistant Prostate Cancer Treatment in the PSMA PET Era - Neal Shore Details Zach Klaassen discusses the evolving landscape of non-metastatic castration-resistant prostate cancer (nmCRPC) with Neal Shore. They delve into the significant impact of PSMA PET scans on diagnosing and treating nmCRPC. Dr. Shore reflects on three pivotal trials—SPARTAN, PROSPER, and ARAMIS—that have redefined treatment approaches by demonstrating the efficacy of apalutamide, enzalutamide, and dar...
Non-Metastatic Castration-Resistant Prostate Cancer in the Era of PSMA PET Imaging - Aaron Berger Details Zach Klaassen and Aaron Berger explore the evolving landscape of non-metastatic castration-resistant prostate cancer (nmCRPC). Dr. Berger highlights the decreasing frequency of non-metastatic CRPC in clinical settings, attributing this shift to advanced imaging techniques, especially PSMA PET scans, which more accurately detect metastatic stages. He notes that in 2022 and 2023, only about 8% of ne...
Managing Nonmetastatic Castration-Resistant Prostate Cancer - Zachary Reardon Details Zach Klaassen and Zach Reardon delve into the nuances of managing nonmetastatic castration-resistant prostate cancer (nmCRPC) in clinical practice. Dr. Reardon discusses the evolving landscape of nmCRPC treatment, emphasizing the significance of early detection and the impact of advancing imaging technologies like PSMA PET scans on patient categorization. He advocates for treating patients with de...
Care for Patients with Nonmetastatic Castration-Resistant Prostate Cancer - Hanan Goldberg Details Zach Klaassen and Hanan Goldberg discuss the evolving landscape of nonmetastatic castration-resistant prostate cancer (nmCRPC), highlighting the impact of PSMA PET scans on diminishing this patient category. They ponder the treatment conundrum posed by early detection of metastasis, not covered under current FDA approvals for medications like enzalutamide, apalutamide, and darolutamide, which have...
The Impact of Advanced Imaging on Detection and Treatment in Nonmetastatic CRPC - Vahan Kassabian Details Zach Klaassen engages in a discussion with Vahan Kassabian about the evolving landscape of nonmetastatic castration-resistant prostate cancer (nmCRPC) management. They delve into how novel imaging techniques, particularly PSMA PET scans, have had an impact in diagnosing nmCRPC by identifying metastases not detected by traditional imaging. Dr. Kassabian highlights the importance of PSA kinetics in...
Navigating the Nuances: Exploring Imaging Options and Impact to Treatment Strategies in nmCRPC - Ryan Malone Details Zach Klaassen and Ryan Malone discuss the management of Nonmetastatic castration-resistant prostate cancer (nmCRPC), focusing on the evolving role of PSMA PET imaging. They highlight the importance of defining PSA progression and the challenges posed by new imaging techniques in identifying low-volume disease. The discussion covers landmark trials and their implications for treatment options, emph...